Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer.

Epstein-Peterson ZD, Devlin SM, Stein EM, Klimek VM, Saltz LB, Tallman MS.

Leuk Res. 2019 Jul;82:19-23. doi: 10.1016/j.leukres.2019.05.010. Epub 2019 May 24.

PMID:
31151028
2.

How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy.

Heuser M, Mina A, Stein EM, Altman JK.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:411-420. doi: 10.1200/EDBK_238687. Epub 2019 May 17.

PMID:
31099617
3.

Intraocular B-cell Acute Lymphoblastic Leukemia.

Francis JH, Orlin A, Stein EM.

Ophthalmol Retina. 2018 Aug;2(8):826. doi: 10.1016/j.oret.2018.03.002. Epub 2018 Aug 2. No abstract available.

PMID:
31047536
4.

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.

Pollyea DA, Tallman MS, de Botton S, Kantarjian HM, Collins R, Stein AS, Frattini MG, Xu Q, Tosolini A, See WL, MacBeth KJ, Agresta SV, Attar EC, DiNardo CD, Stein EM.

Leukemia. 2019 Apr 9. doi: 10.1038/s41375-019-0472-2. [Epub ahead of print]

PMID:
30967620
5.
6.

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.

Stein EM, DiNardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK, Roboz GJ, Patel MR, Collins R, Flinn IW, Sekeres MA, Stein AS, Kantarjian HM, Levine RL, Vyas P, MacBeth KJ, Tosolini A, VanOostendorp J, Xu Q, Gupta I, Lila T, Risueno A, Yen KE, Wu B, Attar EC, Tallman MS, de Botton S.

Blood. 2019 Feb 14;133(7):676-687. doi: 10.1182/blood-2018-08-869008. Epub 2018 Dec 3.

7.

Disrupted radial and tibial microarchitecture in patients with monoclonal gammopathy of undetermined significance.

Stein EM, Dash A, Bucovsky M, Agarwal S, Fu J, Lentzsch S, Shane E.

Osteoporos Int. 2019 Mar;30(3):629-635. doi: 10.1007/s00198-018-4787-z. Epub 2018 Nov 28.

PMID:
30488275
8.

Urinary N-Telopeptide Can Predict Pseudarthrosis After Anterior Cervical Decompression and Fusion: A Prospective Study.

Steinhaus ME, Hill PS, Yang J, Feuchtbaum E, Bronheim RS, Prabhakar P, Lafage V, Carlson BB, Saville P, Albert TJ, Lafage R, Stein EM, Kim HJ.

Spine (Phila Pa 1976). 2019 Jun 1;44(11):770-776. doi: 10.1097/BRS.0000000000002935.

PMID:
30475338
9.

SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.

DiNardo CD, Stein EM.

Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):769-772. doi: 10.1016/j.clml.2018.10.007. Epub 2018 Oct 21. Review.

PMID:
30416011
10.

Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.

Harding JJ, Lowery MA, Shih AH, Schvartzman JM, Hou S, Famulare C, Patel M, Roshal M, Do RK, Zehir A, You D, Selcuklu SD, Viale A, Tallman MS, Hyman DM, Reznik E, Finley LWS, Papaemmanuil E, Tosolini A, Frattini MG, MacBeth KJ, Liu G, Fan B, Choe S, Wu B, Janjigian YY, Mellinghoff IK, Diaz LA, Levine RL, Abou-Alfa GK, Stein EM, Intlekofer AM.

Cancer Discov. 2018 Dec;8(12):1540-1547. doi: 10.1158/2159-8290.CD-18-0877. Epub 2018 Oct 24.

PMID:
30355724
11.

Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States.

Stein EM, Yang M, Guerin A, Gao W, Galebach P, Xiang CQ, Bhattacharyya S, Bonifacio G, Joseph GJ.

Health Qual Life Outcomes. 2018 Sep 21;16(1):193. doi: 10.1186/s12955-018-1013-9.

12.

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.

Fathi AT, Erba HP, Lancet JE, Stein EM, Ravandi F, Faderl S, Walter RB, Advani AS, DeAngelo DJ, Kovacsovics TJ, Jillella A, Bixby D, Levy MY, O'Meara MM, Ho PA, Voellinger J, Stein AS.

Blood. 2018 Sep 13;132(11):1125-1133. doi: 10.1182/blood-2018-03-841171. Epub 2018 Jul 25.

PMID:
30045838
13.

The fatal outcomes of failed prevention.

Stein EM, Remington PL.

Lancet Public Health. 2018 Aug;3(8):e354-e355. doi: 10.1016/S2468-2667(18)30140-3. Epub 2018 Jul 21. No abstract available.

14.

Lower Spine Volumetric Bone Density in Patients With a History of Epidural Steroid Injections.

Liu Y, Carrino JA, Dash AS, Chukir T, Do H, Bockman RS, Hughes AP, Press JM, Stein EM.

J Clin Endocrinol Metab. 2018 Sep 1;103(9):3405-3410. doi: 10.1210/jc.2018-00558.

PMID:
29982535
15.

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.

Intlekofer AM, Shih AH, Wang B, Nazir A, Rustenburg AS, Albanese SK, Patel M, Famulare C, Correa FM, Takemoto N, Durani V, Liu H, Taylor J, Farnoud N, Papaemmanuil E, Cross JR, Tallman MS, Arcila ME, Roshal M, Petsko GA, Wu B, Choe S, Konteatis ZD, Biller SA, Chodera JD, Thompson CB, Levine RL, Stein EM.

Nature. 2018 Jul;559(7712):125-129. doi: 10.1038/s41586-018-0251-7. Epub 2018 Jun 27.

16.

Abnormal microarchitecture and stiffness in postmenopausal women using chronic inhaled glucocorticoids.

Liu Y, Dimango E, Bucovsky M, Agarwal S, Nishiyama K, Guo XE, Shane E, Stein EM.

Osteoporos Int. 2018 Sep;29(9):2121-2127. doi: 10.1007/s00198-018-4591-9. Epub 2018 Jun 11.

PMID:
29947865
17.

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM.

N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2.

18.

FLT3 inhibitors for relapsed or refractory acute myeloid leukaemia.

Stein EM.

Lancet Oncol. 2018 Jul;19(7):849-850. doi: 10.1016/S1470-2045(18)30335-8. Epub 2018 May 31. No abstract available.

PMID:
29859852
19.

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.

Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, Jongen-Lavrenic M, Altman JK, Thomson B, Blakemore SJ, Daigle SR, Waters NJ, Suttle AB, Clawson A, Pollock R, Krivtsov A, Armstrong SA, DiMartino J, Hedrick E, Löwenberg B, Tallman MS.

Blood. 2018 Jun 14;131(24):2661-2669. doi: 10.1182/blood-2017-12-818948. Epub 2018 May 3.

20.

Time to repeal and replace response criteria for acute myeloid leukemia?

Bloomfield CD, Estey E, Pleyer L, Schuh AC, Stein EM, Tallman MS, Wei A.

Blood Rev. 2018 Sep;32(5):416-425. doi: 10.1016/j.blre.2018.03.006. Epub 2018 Mar 27. Review.

21.

Widespread use of measurable residual disease in acute myeloid leukemia practice.

Epstein-Peterson ZD, Devlin SM, Stein EM, Estey E, Tallman MS.

Leuk Res. 2018 Apr;67:92-98. doi: 10.1016/j.leukres.2018.02.006. Epub 2018 Feb 13.

PMID:
29482173
22.

The Effect of Race in Patients with Achalasia Diagnosed With High-Resolution Esophageal Manometry.

Chedid V, Rosenblatt E, Gandhi KK, Dhalla S, Nandwani MC, Stein EM, Clarke JO.

Am J Med Sci. 2018 Feb;355(2):126-131. doi: 10.1016/j.amjms.2017.11.004. Epub 2017 Nov 13.

PMID:
29406039
23.

Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.

Fathi AT, DiNardo CD, Kline I, Kenvin L, Gupta I, Attar EC, Stein EM, de Botton S; AG221-C-001 Study Investigators.

JAMA Oncol. 2018 Aug 1;4(8):1106-1110. doi: 10.1001/jamaoncol.2017.4695.

24.

Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations.

Stein EM, Bonifacio G, Latremouille-Viau D, Guerin A, Shi S, Gagnon-Sanschagrin P, Briggs O, Joseph GJ.

J Med Econ. 2018 Jun;21(6):556-563. doi: 10.1080/13696998.2018.1425209. Epub 2018 Jan 22.

PMID:
29304724
25.

Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.

Stein EM.

Future Oncol. 2018 Jan;14(1):23-40. doi: 10.2217/fon-2017-0392. Epub 2017 Sep 18.

PMID:
29243965
26.

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.

Singleton KR, Crawford L, Tsui E, Manchester HE, Maertens O, Liu X, Liberti MV, Magpusao AN, Stein EM, Tingley JP, Frederick DT, Boland GM, Flaherty KT, McCall SJ, Krepler C, Sproesser K, Herlyn M, Adams DJ, Locasale JW, Cichowski K, Mukherjee S, Wood KC.

Cell Rep. 2017 Dec 5;21(10):2796-2812. doi: 10.1016/j.celrep.2017.11.022.

27.

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.

Stein EM, Walter RB, Erba HP, Fathi AT, Advani AS, Lancet JE, Ravandi F, Kovacsovics T, DeAngelo DJ, Bixby D, Faderl S, Jillella AP, Ho PA, O'Meara MM, Zhao B, Biddle-Snead C, Stein AS.

Blood. 2018 Jan 25;131(4):387-396. doi: 10.1182/blood-2017-06-789800. Epub 2017 Dec 1.

28.

Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders.

Pasricha PJ, Yates KP, Sarosiek I, McCallum RW, Abell TL, Koch KL, Nguyen LAB, Snape WJ, Hasler WL, Clarke JO, Dhalla S, Stein EM, Lee LA, Miriel LA, Van Natta ML, Grover M, Farrugia G, Tonascia J, Hamilton FA, Parkman HP; NIDDK Gastroparesis Clinical Research Consortium (GpCRC).

Gastroenterology. 2018 Jan;154(1):65-76.e11. doi: 10.1053/j.gastro.2017.08.033. Epub 2017 Oct 28.

29.

The Epidemic of Despair Among White Americans: Trends in the Leading Causes of Premature Death, 1999-2015.

Stein EM, Gennuso KP, Ugboaja DC, Remington PL.

Am J Public Health. 2017 Oct;107(10):1541-1547. doi: 10.2105/AJPH.2017.303941. Epub 2017 Aug 17.

30.

Minimal Residual Disease in Acute Myeloid Leukemia: Prognostication and Pitfalls.

Stein EM.

J Oncol Pract. 2017 Aug;13(8):485-486. doi: 10.1200/JOP.2017.025338. No abstract available.

PMID:
28796969
31.

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.

Anderson GR, Winter PS, Lin KH, Nussbaum DP, Cakir M, Stein EM, Soderquist RS, Crawford L, Leeds JC, Newcomb R, Stepp P, Yip C, Wardell SE, Tingley JP, Ali M, Xu M, Ryan M, McCall SJ, McRee AJ, Counter CM, Der CJ, Wood KC.

Cell Rep. 2017 Jul 25;20(4):999-1015. doi: 10.1016/j.celrep.2017.07.006.

32.

Prevalence and predictors of pain and opioid analgesic use following total pancreatectomy with islet autotransplantation for pancreatitis.

Moran RA, Klapheke R, John GK, Devlin S, Warren D, Desai N, Sun Z, Walsh C, Kalyani RR, Hall E, Stein EM, Kalloo AN, Zaheer A, Hirose K, Makary MA, Singh VK.

Pancreatology. 2017 Sep - Oct;17(5):732-737. doi: 10.1016/j.pan.2017.07.005. Epub 2017 Jul 12.

PMID:
28733148
33.

Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia.

Getta BM, Roshal M, Zheng J, Park JH, Stein EM, Levine R, Papadopoulos EB, Jakubowski AA, Kernan NA, Steinherz P, O'Reilly RJ, Perales MA, Giralt SA, Tallman MS, Shaffer BC.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1879-1886. doi: 10.1016/j.bbmt.2017.06.026. Epub 2017 Jul 8.

34.

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS.

Blood. 2017 Aug 10;130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6.

35.

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.

Amatangelo MD, Quek L, Shih A, Stein EM, Roshal M, David MD, Marteyn B, Farnoud NR, de Botton S, Bernard OA, Wu B, Yen KE, Tallman MS, Papaemmanuil E, Penard-Lacronique V, Thakurta A, Vyas P, Levine RL.

Blood. 2017 Aug 10;130(6):732-741. doi: 10.1182/blood-2017-04-779447. Epub 2017 Jun 6.

36.

What is the clinical significance of esophagogastric junction outflow obstruction? evaluation of 60 patients at a tertiary referral center.

Okeke FC, Raja S, Lynch KL, Dhalla S, Nandwani M, Stein EM, Chander Roland B, Khashab MA, Saxena P, Kumbhari V, Ahuja NK, Clarke JO.

Neurogastroenterol Motil. 2017 Jun;29(6). doi: 10.1111/nmo.13061. Epub 2017 Apr 9.

PMID:
28393437
37.

Peroral endoscopic myotomy achieves similar clinical response but incurs lesser charges compared to robotic heller myotomy.

Khashab MA, Kumbhari V, Tieu AH, El Zein MH, Ismail A, Ngamruengphong S, Singh VK, Kalloo AN, Clarke JO, Stein EM.

Saudi J Gastroenterol. 2017 Mar-Apr;23(2):91-96. doi: 10.4103/1319-3767.203360.

38.

Three-Dimensional Anorectal Manometry Enhances Diagnostic Gain by Detecting Sphincter Defects and Puborectalis Pressure.

Raja S, Okeke FC, Stein EM, Dhalla S, Nandwani M, Lynch KL, Gyawali CP, Clarke JO.

Dig Dis Sci. 2017 Dec;62(12):3536-3541. doi: 10.1007/s10620-017-4466-5. Epub 2017 Feb 13.

PMID:
28194667
39.

Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.

Shih AH, Meydan C, Shank K, Garrett-Bakelman FE, Ward PS, Intlekofer AM, Nazir A, Stein EM, Knapp K, Glass J, Travins J, Straley K, Gliser C, Mason CE, Yen K, Thompson CB, Melnick A, Levine RL.

Cancer Discov. 2017 May;7(5):494-505. doi: 10.1158/2159-8290.CD-16-1049. Epub 2017 Feb 13.

40.

Aspirin Is Associated with Improved Survival in Severely Thrombocytopenic Cancer Patients with Acute Myocardial Infarction.

Feher A, Kampaktsis PN, Parameswaran R, Stein EM, Steingart R, Gupta D.

Oncologist. 2017 Feb;22(2):213-221. doi: 10.1634/theoncologist.2016-0110. Epub 2017 Feb 3.

41.

Chronic Gastrointestinal Dysmotility and Pain Following Total Pancreatectomy with Islet Autotransplantation for Chronic Pancreatitis.

John GK, Singh VK, Moran RA, Warren D, Sun Z, Desai N, Walsh C, Kalyani RR, Hall E, Hirose K, Makary MA, Stein EM.

J Gastrointest Surg. 2017 Apr;21(4):622-627. doi: 10.1007/s11605-016-3348-z. Epub 2017 Jan 12.

PMID:
28083839
42.

Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.

Mantha S, Goldman DA, Devlin SM, Lee JW, Zannino D, Collins M, Douer D, Iland HJ, Litzow MR, Stein EM, Appelbaum FR, Larson RA, Stone R, Powell BL, Geyer S, Laumann K, Rowe JM, Erba H, Coutre S, Othus M, Park JH, Wiernik PH, Tallman MS.

Blood. 2017 Mar 30;129(13):1763-1767. doi: 10.1182/blood-2016-10-747170. Epub 2017 Jan 12.

43.

PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.

Anderson GR, Wardell SE, Cakir M, Crawford L, Leeds JC, Nussbaum DP, Shankar PS, Soderquist RS, Stein EM, Tingley JP, Winter PS, Zieser-Misenheimer EK, Alley HM, Yllanes A, Haney V, Blackwell KL, McCall SJ, McDonnell DP, Wood KC.

Sci Transl Med. 2016 Dec 14;8(369):369ra175.

44.

Vitamin D Storage in Adipose Tissue of Obese and Normal Weight Women.

Carrelli A, Bucovsky M, Horst R, Cremers S, Zhang C, Bessler M, Schrope B, Evanko J, Blanco J, Silverberg SJ, Stein EM.

J Bone Miner Res. 2017 Feb;32(2):237-242. doi: 10.1002/jbmr.2979. Epub 2016 Oct 24.

45.

Ileus is a predictor of local infection in patients with acute necrotizing pancreatitis.

Moran RA, Jalaly NY, Kamal A, Rao S, Klapheke R, James TW, Kambhampati S, Makary MA, Hirose K, Kumbhari V, Stein EM, Khashab MA, Lennon AM, Kalloo AN, Zaheer A, Hernaez R, Singh VK.

Pancreatology. 2016 Nov - Dec;16(6):966-972. doi: 10.1016/j.pan.2016.10.002. Epub 2016 Oct 3.

PMID:
27727097
46.

Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.

Baljevic M, Dumitriu B, Lee JW, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM, Appelbaum FR, Powell BL, Larson RA, Coutré SE, Lancet J, Litzow MR, Luger SM, Young NS, Tallman MS.

Acta Haematol. 2016;136(4):210-218. Epub 2016 Sep 16.

47.

Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia.

Watts JM, Dumitriu B, Hilden P, Kishtagari A, Rapaport F, Chen C, Ahn J, Devlin SM, Stein EM, Rampal R, Levine RL, Young N, Tallman MS.

Leuk Res. 2016 Oct;49:62-5. doi: 10.1016/j.leukres.2016.07.013. Epub 2016 Jul 25.

48.

Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias.

Wang K, Sanchez-Martin M, Wang X, Knapp KM, Koche R, Vu L, Nahas MK, He J, Hadler M, Stein EM, Tallman MS, Donahue AL, Frampton GM, Lipson D, Roels S, Stephens PJ, Sanford EM, Brennan T, Otto GA, Yelensky R, Miller VA, Kharas MG, Levine RL, Ferrando A, Armstrong SA, Krivtsov AV.

Leukemia. 2017 Jan;31(1):151-158. doi: 10.1038/leu.2016.166. Epub 2016 Jun 13.

49.

Acute myeloid leukemia masquerading as hepatocellular carcinoma.

Abu-Zeinah GF, Weisman P, Ganesh K, Katz SS, Dogan A, Abou-Alfa GK, Stein EM, Jarnagin W, Mauro MJ, Harding JJ.

J Gastrointest Oncol. 2016 Jun;7(3):E31-5. doi: 10.21037/jgo.2015.12.01.

50.

Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia.

Lin KH, Winter PS, Xie A, Roth C, Martz CA, Stein EM, Anderson GR, Tingley JP, Wood KC.

Sci Rep. 2016 Jun 10;6:27696. doi: 10.1038/srep27696.

Supplemental Content

Loading ...
Support Center